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Objectives: To validate a Work Productivity and Activity
Impairment questionnaire (WPAI-GERD) developed to
measure lost productivity due to symptoms of gastro-
esophageal reﬂux disease (GERD).
Methods and Data: The WPAI-GERD was administered
along with two quality-of-life questionnaires, Quality of
Life in Reﬂux and Dyspepsia (QOLRAD) and Short Form
36 (SF-36), to a Swedish working population (N = 136)
visiting a general practitioner for symptoms attributed to
GERD. Correlation coefﬁcients were calculated between
each productivity variable derived from the WPAI-GERD
and symptom severity, symptom frequency, quality of life
dimensions, age, and gender. Statistical tests were carried
out to determine the relationship between each produc-
tivity variable and the severity of heartburn.
Results: High correlations (range: 0.30–0.75) were found
between productivity and symptom severity as well as
between productivity and quality-of-life dimensions
related to work and daily activities. The results demon-
strated the ability of the questionnaire to discriminate
between different grades of heartburn severity. On
average, patients with heartburn reported 2.5 hours
absence from work, 23% reduced productivity while at
work, and 30% reduced productivity while doing regular
daily activities during the week preceding the consulta-
tion. The SF-36 scores implied that patients, especially
those with moderate-to-severe heartburn, had a poor
quality of life compared with a normal population.
Conclusion: The results indicate a high convergent and
discriminant validity of the WPAI-GERD questionnaire
and also show that patients consulting a physician
because of symptoms attributed to GERD report sub-
stantial impairment in both productivity and health-
related quality of life.
Keywords: GERD, GORD, heartburn, indirect costs, pro-
ductivity, validity, quality of life.
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Studies of indirect costs in economic evaluations
often focus on loss of productivity due to absence
from work and early retirement due to disease.
Reduced productivity while at work and loss of 
productivity in unpaid activities attributable to a
disease have been given less attention, even though
such variables are identiﬁed as being important
indirect cost components [1,2]. A self-administered
Work Productivity and Activity Impairment (WPAI)
questionnaire has been developed by Reilly and
coworkers [3] and validated in patients with aller-
gic rhinitis [4]. A similar questionnaire has also
been used to assess the impact of migraine on pro-
ductivity [5]. The WPAI questionnaire includes
questions about time lost from work, reduced pro-
ductivity while at work, and reduced productivity
while doing regular daily activities. The question-
naire can be used in intervention studies as well as
in burden-of-illness studies, and the results can be
used both for descriptive purposes and in economic
evaluations.
Gastro-esophageal reﬂux disease (GERD) is con-
sidered a chronic disease with a high prevalence
and, to a large extent, afﬂicts patients in an active
phase of their lives [6,7]. It has been estimated that
25% of the Swedish population suffers from GERD
symptoms, which were the predominant symptoms
in one-third of the affected population [8]. Typical
symptoms of GERD include heartburn and acid
regurgitation, of which heartburn is considered the
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most frequent marker for GERD [6]. Studies have
shown that GERD symptoms adversely affect
patients’ everyday life and health-related quality of
life (HRQL) [7,9–12]. Furthermore, HRQL seems
to be equally impaired whether the patient with
GERD has erosion of the esophagus or not [13,14],
which indicates that symptom control is an impor-
tant target for any medical intervention. Results of
a recent US survey indicate that reduced productiv-
ity while at work is a signiﬁcant economic factor in
patients with GERD [15]. To our knowledge, there
is no validated disease-speciﬁc questionnaire avail-
able for use in intervention or burden-of-illness
studies to measure reduced productivity attribut-
able to GERD while at work or while doing regular
daily activities. We modiﬁed the original WPAI into
a questionnaire designed to measure lost produc-
tivity due to symptoms of GERD (WPAI-GERD)
and tested it in a cross-sectional study of a Swedish
working population with symptoms of GERD. The
main purpose of this study was to validate the
WPAI-GERD questionnaire and to examine to 
what extent patients with GERD symptoms report
absence from work, reduced productivity while at
work, and reduced productivity while doing regular
daily activities.
Patients and Methods
The WPAI-GERD was administered to a Swedish
working population made up of patients who 
had consulted a general practitioner (GP) because
they were experiencing or had experienced GERD
symptoms, deﬁned as heartburn or acid regurgita-
tion. A validated GERD-speciﬁc HRQL question-
naire, Quality of Life in Reﬂux and Dyspepsia
(QOLRAD) [16], and a validated generic question-
naire, Short Form-36 (SF-36) [17], were coadmin-
istered. Data on patient characteristics and GERD
symptoms were recorded by the GP on case report
forms. The study was supervised by a contract
research organization, Navigare Medical Marketing
Research AB.
Inclusion and Exclusion Criteria
The study inclusion criteria were: patients currently
employed and/or self-employed whose reason for
the visit was current or previous symptoms of
GERD deﬁned as heartburn or acid regurgitation;
patients with episodes of mild, moderate, or severe
heartburn for 1 or more of the 7 days preceding the
visit; female or male, aged 18 to 65 years, who had
signed informed consent to participate in the study.
The exclusion criteria were: any alarm symptoms
indicating serious or malignant disease, alcohol or
drug abuse, mental illness/dementia or any condi-
tion that could contribute to poor compliance with
the study procedures, inability to understand or
complete the questionnaires, and previous partici-
pation in the study. One of the initial inclusion 
criteria was that the patient have had a minimum
of 1 day with at least mild heartburn symptoms
during the previous week. This criterion was used
to select a minimum of 100 consecutive patients
with mild, moderate, or severe heartburn symp-
toms. Once this target had been reached, the inclu-
sion criterion was changed to select for patients
with no heartburn during the 7 days prior to the
visit, and at least 25 GERD patients with no heart-
burn symptoms during the previous week were
included in the study. The patients with no heart-
burn served as a reference group to investigate the
ability of the WPAI-GERD to discriminate between
the symptomatic and asymptomatic GERD popula-
tions. The inclusion of patients with and without
heartburn was done sequentially instead of in par-
allel for practical reasons regarding the study setup.
Case Report Forms
Severity (none, mild, moderate, severe) and fre-
quency (1–7 days) of GERD symptoms during the
previous week were recorded by the GP on case
report forms. Mild symptoms were deﬁned as
awareness of symptom but easily tolerated, moder-
ate symptoms as discomfort sufﬁcient to cause
interference with normal activities, and severe
symptoms as incapacitating with inability to
perform normal activities. Furthermore, demo-
graphic data such as the patients’ age in years and
gender were collected, as was information regard-
ing whether an upper gastrointestinal endoscopy
had been performed during the past year, and if so,
whether the patient had been diagnosed as having
reﬂux esophagitis.
WPAI-GERD
All questions included on the WPAI-GERD related
to the previous 7 days, and GERD symptoms were
deﬁned as heartburn or acid regurgitation. Two
questions not included in the original WPAI were
added for descriptive purposes: one question on
days worked in total and one question on days with
GERD symptoms to which responses are given
using tick boxes corresponding to the number of
days (0–7). These are followed by three open-ended
questions about work time: hours absent from work
because of GERD symptoms, hours absent from
work for other reasons, and hours actually worked.
108 Wahlqvist et al.
Finally, one question to determine the average
percent reduction in productivity at work attributed
to GERD symptoms and one question about the
average percent reduction in productivity while
doing regular daily activities during the previosu 
7 days are asked. All types of activities outside of
work are included in the deﬁnition of regular daily
activities, such as housework, schoolwork, and
leisure activities. The questions about reduced pro-
ductivity were modiﬁed so that the percent reduc-
tion in productivity could be determined directly by
answers given on a visual analogue scale that range
from a 0% to 100% reduction with anchoring
points at every 10%. This is a different approach
than that used in the original WPAI questionnaire
developed by Reilly and coworkers, where the esti-
mated percent reduction in productivity is derived
from responses using an 11-point Likert scale with
a range of 0 to 10 representing levels of productiv-
ity. The response scale used in the WPAI-GERD
question on reduced productivity while at work is
displayed in Figure 1. More information about the
WPAI-GERD used in this study can be obtained
from the corresponding author.
The main aims when choosing the WPAI as the
preferred productivity questionnaire and when
modifying it were that the questionnaire should: 1)
be self-administered; 2) be short and simple so that
it could be used in clinical trials; 3) have a short
recall period to avoid recall bias; 4) be sensitive
enough to record a small amount of lost produc-
tivity; and 5) be sensitive in terms of validity, relia-
bility, and responsiveness to changes in symptoms.
QOLRAD
The questions in the self-administered QOLRAD
are phrased to relate to the impact of heartburn and
acid regurgitation on the patient’s HRQL during 
the previous week. The questionnaire has 25 items
combined into ﬁve dimensions to evaluate emo-
tional distress: sleep disturbance, food and drink
problems, physical and social functioning, and
vitality. A seven-point Likert scale is used to assess
how much and how often the patient experienced
the symptom in terms of the degree of distress that
it provoked (none at all, hardly any, a little, some,
a moderate amount, a lot, a great deal) and its per-
sistence (none of the time, hardly any of the time,
a little of the time, some of the time, quite a lot 
of the time, most of the time, all of the time). For
each dimension, one of seven possible answers is
selected. The lower the score, the greater is the 
negative impact on HRQL. The QOLRAD has been
tested for validity, reliability, and responsiveness to
change over time [16,18].
SF-36
The self-administered SF-36 contains 36 items
related to the impact of the current health status 
on the patient’s HRQL during the previous week. It
covers eight dimensions: physical functioning, role
physical, bodily pain, general health, vitality, social
functioning, role emotional, and mental health [17].
The range of the SF-36 scale is from 0 to 100, and
the higher the value in each HRQL dimension, the
better the patient’s HRQL. The SF-36 is a well-
documented generic health-status instrument [19]
that has been widely used in a variety of diseased
populations and in samples of the general popula-
tion to derive reference values [17,20].
Methodological Considerations
The productivity variables considered relevant 
for validation purposes were: absence from work,
average reduced productivity while working,
average reduced productivity while performing
daily activities, and a lost work productivity score
(LWPS). The LWPS expresses lost work productiv-
ity attributed to GERD symptoms for each pa-
tient as a percentage of the potential total work 
productivity:
LWPS = [(hours absent from work + percentage
reduced productivity at work ¥ hours actually
worked)/(hours absent from work + hours lost due
to other reasons + hours actually worked)] ¥ 100.
Values for each productivity variable were cal-
culated per patient without considering missing
data points. Reduced productivity while at work
was calculated per patient at work during the 
previous week. However, LWPS were calculated 
and were reported as zero for patients who were
employed but did not work at all during the previ-
ous week for reasons other than GERD symptoms.
HRQL scores were calculated using established
methods for handling missing data [17,21].
Pearson correlation coefﬁcients were calculated
to determine the correlation between each produc-
tivity variable (absence from work, reduced pro-
ductivity while at work, reduced productivity while
doing regular daily activities, LWPS) and GERD
Productivity       (PUT A CROSS [X] ON THE SCALE) Unable
not affected to work
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Figure 1 Response scale used in the WPAI-GERD question on
reduced productivity while at work.
109Productivity in GERD
symptoms, each dimension of the HRQL question-
naires, age, and gender. To test whether correlation
coefﬁcients were signiﬁcantly different from zero, p-
values were calculated at a 5% level of signiﬁcance
(adjusted for multiplicity using the Bonferroni
inequality method). The validity of the WPAI-
GERD was assessed in accordance with the best
psychometric techniques available for validating
HRQL questionnaires [20,22–26]. A general and
established deﬁnition of validity is whether the
instrument measures what it is intended to measure.
Although different forms of validity can be consid-
ered, construct validity was the most appropriate
for the WPAI questionnaire in this study. Construct
validity refers to whether the measured variables
behave in a way that is consistent with theoretical
and logical expectations. Construct validity is
usually divided into convergent and discriminant
validity.
Convergent validity is deﬁned as whether the
measured variables correlate with other measures of
the same concept. Evidence of convergent validity
was deﬁned in the present study as a high and sta-
tistically signiﬁcant (p < .05) correlation between
each productivity variable and other variables
where expected. In terms of HRQL dimensions, the
highest correlation was expected to be with the
QOLRAD dimension “physical/social functioning,”
which includes speciﬁc questions on how GERD
symptoms impact on work and daily activities.
When examining the SF-36 dimensions, productiv-
ity loss due to GERD would most likely be corre-
lated with the dimension “role physical,” which
includes questions on the impact of the current
physical health status on work and daily activities.
Even though symptoms and lost productivity by
deﬁnition are not variables of the same construct,
an association between severity and frequency of
GERD symptoms and reported loss of productivity
due to GERD was expected, particularly with sever-
ity of heartburn. It is difﬁcult to determine what
constitutes a high or low correlation, but based on
previous experiences in validating WPAI [4] and
HRQL [16] questionnaires, a correlation coefﬁcient
above 0.30 was considered high for absence from
work and above 0.40 for the other productivity
variables. A correlation coefﬁcient below 0.20 was
deﬁned as a low correlation.
Discriminant validity is deﬁned as a low correla-
tion between the measured variables and measures
of a different concept, as well as an ability to dif-
ferentiate between groups expected to differ in
terms of the measured variable. In this study, evi-
dence of high discriminant validity was deﬁned as
a low correlation between each productivity vari-
able and other variables where expected. Low cor-
relation was expected between productivity and 
the SF-36 dimensions “general health” and “mental
health,” between productivity and age as well as
gender. Evidence of high discriminant validity was
further deﬁned as a strong relationship between
each productivity variable and the severity of heart-
burn (none, mild, moderate, severe), the predomi-
nant GERD symptom. This relationship was
investigated by carrying out statistical tests to deter-
mine whether there was a statistically signiﬁcant
difference in each productivity variable between
patients with and without heartburn symptoms,
and whether the correlation between each produc-
tivity variable and heartburn severity was statisti-
cally signiﬁcant.
Results
One hundred nine patients with mild-to-moderate
heartburn symptoms were consecutively recruited
between October 1998 and January 1999 by GPs
in the southwestern regions of Sweden. Twenty-
seven patients with no heartburn symptoms were
consecutively recruited between January and April
1999.
Patient Characteristics
The proportion of males to females in the study was
70 to 66 with a mean age of 42.7 years (range
18–63). Gender distribution and mean age were
similar among patients with (55/54, 42.5 years) and
without (15/12, 43.8 years) heartburn symptoms.
An upper gastrointestinal endoscopy had been per-
formed in 14 (10%) of the total 136 patients during
the past year. In 6 (43%) of those 14 patients, a
diagnosis of reﬂux esophagitis was made. Data on
severity and frequency of heartburn and acid regur-
gitation, summarized in Table 1, show that the
majority (64 of 109) of patients with heartburn had
moderate symptoms. The mean number of days
with heartburn was 4.6 (SD = 2.0 days) and with
acid regurgitation 3.3 (SD = 2.3 days) in patients
with mild-to-severe heartburn.
HRQL
The results of the disease-speciﬁc HRQL question-
naire, QOLRAD, are shown in Table 2 and the
results of the generic HRQL questionnaire, SF-36,
are shown in Figure 2. The SF-36 scores have been
divided into two groups of patients, one with either
no or mild heartburn symptoms and the other with
moderate-to-severe heartburn symptoms, given that
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results were rather similar within these patient
groups. SF-36 values for a Swedish normal popula-
tion collected in another study [17] are also dis-
played in Figure 2, and SF-36 values were
considerably lower in our study population.
Productivity
The response rate for the WPAI-GERD was very
high in this study, with data missing for only 0.7%
of the answers. Patients with mild-to-severe heart-
burn reported an average of 4.6 days worked during
the previous week, during which GERD symptoms
were present for 3.4 days, or 74% of working days.
Lost productivity due to GERD symptoms
increased with the severity of heartburn, as shown
in Table 3. Patients with mild-to-severe heartburn
symptoms were absent from work for an average of
2.5 hours, productivity while working was reduced
by an average of 23%, and productivity while per-
forming regular daily activities by an average of
30%. The difference between patients with mild-to-
severe heartburn and those with no heartburn was
calculated for each productivity variable, including
95% conﬁdence intervals (CI) for the differences.
This resulted in an average difference between the
two severity groups of 2.4 (CI 1.1–3.7) hours
absence from work, 17% (CI 12–23%) units of
reduced productivity while at work and 20% (CI
15–25%) units of reduced productivity while doing
regular daily activities. Thus, the differences in each
productivity variable between patients with mild-
to-severe heartburn and patients without heartburn
were all statistically signiﬁcant.
Correlation Analysis
The results of the correlation analysis are presented
in Table 4. The higher the value in each dimension,
the better the patient’s HRQL, and loss in produc-
tivity can be expected to be lower. All correlations
indicated that lost productivity was related to the
severity and frequency of GERD symptoms as well
as impaired HRQL.
Validity Assessment
Convergent validity: High and statistically signiﬁ-
cant correlation was found for all dimensions in the
disease-speciﬁc questionnaire and dimensions in 
the generic questionnaire related to the impact of
current state of health on work or daily activities
(Table 4). The highest correlation was, as expected,
between productivity and the QOLRAD dimension
“physical/social functioning.” Furthermore, pro-
ductivity was highly correlated with the SF-36
dimension “role physical.” In terms of speciﬁc




Symptom intensity % n % n
None 0 0 16 17
Mild 28 30 35 38
Moderate 59 64 41 45
Severe 14 15 8 9
Table 2 Health-related quality of life, QOLRAD scores
(standard deviations) by severity of heartburn
Heartburn severity
QOLRAD variable Absent Mild Moderate Severe
Emotional distress 6.3 (0.8) 5.1 (1.3) 4.3 (1.3) 3.9 (1.5)
Sleep disturbance 6.3 (1.1) 5.4 (1.2) 4.2 (1.6) 4.3 (1.5)
Food and drink 
problems 6.0 (1.1) 4.9 (0.9) 4.0 (1.1) 3.6 (1.2)
Physical/social 
functioning 6.6 (0.7) 6.1 (0.7) 5.0 (1.2) 4.5 (1.4)














































 Swedish norm population 
 Patients with no to mild heartburn (N=57) 
 Patients with moderate to severe heartburn (N=79) 
Figure 2 Health-related quality of life, SF-36 scores in a Swedish
norm population and in patients with no-to-mild and moderate-to-
severe heartburn symptoms.
Table 3 Loss of productivity (standard deviations) by sever-
ity of heartburn
Severity of AW (SD) PW (SD) PA (SD) LWPS (SD)
heartburn hours % % %
Absent 0.1 (0.4) 6 (10) 8 (11) 4 (9)
Mild 0.4 (1.5) 16 (13) 19 (15) 16 (13)
Moderate 2.4 (5.5) 25 (20) 30 (23) 25 (22)
Severe 7.0 (13.1) 32 (27) 48 (26) 35 (33)
Abbreviations:AW, absence from work; LWPS, lost work productivity score; PA,
average reduced productivity while doing regular daily activities; PW, average
reduced productivity while working.
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GERD symptoms, the highest correlation was
found to be with severity of heartburn, as expected.
Discriminant validity: The lowest correlations
for each productivity variable were with age,
gender, and the SF-36 dimension “general health”
(Table 4). A statistically signiﬁcant difference in
each productivity variable was found between
patients with mild-to-severe heartburn and patients
without heartburn symptoms. Furthermore, the
correlation between each productivity variable and
heartburn severity was statistically signiﬁcant.
Discussion
In terms of symptoms assessed by the GPs, the cor-
relation analysis showed that the strongest rela-
tionship was between productivity and severity of
heartburn. This was expected, because heartburn 
is considered to be the predominant symptom of
GERD and earlier studies have shown that there is
a higher correlation between HRQL and symptom
severity than between HRQL and symptom fre-
quency [16]. The fact that correlation coefﬁcients
between productivity and heartburn severity
assessed by physicians are lower than correlation
coefﬁcients between productivity and the HRQL
reported by patients is also as expected, since there
is a discrepancy between the physicians’ assess-
ments and those made by the patients themselves
[27]. The correlation coefﬁcients for absence from
work were generally lower than for other produc-
tivity variables, which is explained by the fact that
the majority of patients reported no (i.e., zero
hours) absence from work. For example, only 23%
of the patients with mild-to-severe heartburn
reported any absence from work attributed to
GERD symptoms, with a mean of 10.5 working
hours missed by these patients. The ﬁnding that
patients without heartburn symptoms also reported
a small amount of lost productivity is probably a
result of measurement errors with respect to ﬂoor
effects or due to the discrepancy between symptom
ratings made by the physician and the patients
themselves. However, it is difﬁcult to assess the
impact of this discrepancy on the study results. Cor-
relation coefﬁcients were generally higher between
each productivity variable and dimensions of the
disease-speciﬁc QOLRAD than the dimensions of
the generic SF-36. This was also expected, because
the questions in the QOLRAD focus on the impact
of GERD symptoms on HRQL. When examining
the questions in each dimension more closely, the
highest correlation would be expected between each
of the productivity variables and the QOLRAD
dimension “physical/social functioning,” which was
conﬁrmed in this study. A higher correlation exists
between productivity and the SF-36 dimension
“mental health” than was anticipated. However,
mental-health status may affect how patients per-
ceive GERD symptoms [28] as well as the impact
of these symptoms on productivity. In fact, most
dimensions of the SF-36 include questions that can
be directly or indirectly related to the impact of 
the current health status on work or regular daily
activities.
The comparison between SF-36 values from our
study and values from a Swedish norm population
represented in Figure 2 indicates that HRQL was
substantially impaired in the symptomatic study
population, especially in patients with moderate-to-
severe heartburn. A difference of ﬁve units in any
of the SF-36 dimensions is considered to be clini-
cally relevant [20]. However, it should be noted that
a comparison of results between two study popula-
tions should be interpreted with caution, because
differences in comorbidity and demographic char-
acteristics could explain some of the differences.
The SF-36 values from our study were actually
lower than other SF-36 values found in clinical
studies of patients with GERD [9–12]. This raises
some concern that our study population may not be
representative of the general GERD population.
Table 4 Pearson correlation coefﬁcients
SF-36 dimensions AW PW PA LWPS
Physical functioning -0.13 -0.32* -0.24 -0.24
Role physical -0.29* -0.51* -0.44* -0.49*
Bodily pain -0.20 -0.43* -0.43* -0.40*
General health 0.06 -0.16 -0.17 -0.09
Vitality -0.30* -0.46* -0.47* -0.43*
Social functioning -0.36* -0.49* -0.56* -0.50*
Role emotional -0.32* -0.35* -0.35* -0.36*
Mental health -0.26 -0.36* -0.38* -0.34*
QOLRAD dimensions
Emotional distress -0.42* -0.58* -0.66* -0.59*
Sleep disturbance -0.30* -0.53* -0.57* -0.50*
Food and drink problems -0.29* -0.44* -0.59* -0.43*
Physical/social functioning -0.50* -0.67* -0.75* -0.67*
Vitality -0.38* -0.53* -0.65* -0.54*
Other variables
Heartburn severity 0.30* 0.39* 0.51* 0.42*
Heartburn frequency 0.14 0.14 0.36* 0.19
Regurgitation severity 0.28 0.28 0.43* 0.30
Regurgitation frequency 0.24 0.16 0.37* 0.19
Age -0.09 -0.15 -0.23 -0.19
Gender 0.02 -0.05 0.04 -0.04
*p < .05, adjusted for multiplicity.
Abbreviations:AW, absence from work; LWPS, lost work productivity score; PA,
average reduced productivity while doing regular daily activities; PW, average
reduced productivity while working.
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Another concern is that our study only comprised
a working population. However, our SF-36 results
were very similar to SF-36 values from a large inter-
national study of patients with GERD symptoms
who were referred for endoscopy [29]. The
QOLRAD scores were also very similar. One of the
inclusion criteria in our study was that the reason
for the GP visit be that the patient was experienc-
ing or had experienced GERD symptoms. This is an
inclusion criterion not usually used in clinical trials,
in which established GERD patients known to the
physician are more heavily recruited. A plausible
explanation for the low SF-36 results in our study
is that the patients regarded their GERD symptoms
to be worrying and disturbing enough to consult 
a GP, a psychological situation similar to being
referred for endoscopy. If this is the case, the results
from our study may indeed be representative of 
a population consulting a GP in clinical practice
because of GERD symptoms.
The aims of this study were to test the concept
of reduced productivity attributed to GERD and to
assess the validity of the WPAI-GERD question-
naire by using psychometric techniques on cross-
sectional data. There are some speciﬁc limitations
that need to be considered when interpreting the
WPAI-GERD results, which are related to the valid-
ity of the questionnaire. The average reduction in
productivity over the previous 7 days is assessed
with the WPAI-GERD questionnaire, and there is a
risk that patients focus on periods when symptoms
are present and more severe and thus overestimate
the reduction in productivity. Furthermore, we do
not know if a reduction in productivity reported by
the patient corresponds to an actual reduction in
productivity. Ideally, the validity of a questionnaire
should be assessed by comparing the results against
a gold standard for measurement of the same crite-
rion. Such a gold standard is not usually available
in behavioral sciences, and previously well-
documented HRQL questionnaires are often used
as surrogate gold standards for validation purposes.
For the validation of a WPAI questionnaire, a time
and motion study in an actual workplace situation
could in theory be used as a gold standard.
However, such a study is difﬁcult to carry out in
practice [30]. In addition, validity assessments
should be distinguished from assessments of test-
retest reliability and responsiveness to change,
which can only be made with data from repeated
measurements in a study population. Hence, valid-
ity assessments of the WPAI-GERD that can be
made based on psychometric data from a cross-
sectional study such as this one are limited, and the
WPAI-GERD questionnaire requires further testing
in future studies.
Conclusions
Results based on data from this cross-sectional
study indicate a high convergent and discriminant
validity for the WPAI-GERD questionnaire. Fur-
thermore, the study results show that patients con-
sulting a physician because of symptoms associated
with gastro-esophageal reﬂux disease report a sub-
stantial impairment in health-related quality of life
and reduced productivity during the week preced-
ing the consultation.
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